CoChat
Sign Up
Cited by 42Neuroendocrine Tumor Research AdvancesNeuroblastoma Research and TreatmentsLung Cancer Research Studies

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Processing-Independent Quantitation of Chromogranin A in Plasma from Patients with Neuroendocrine Tumors and Small-Cell Lung Carcinomas

Børglum, Tine, Rehfeld, Jens F, Drivsholm, Lars B, Hilsted, Linda·2007·Clinical Chemistry
DOI 10.1373/clinchem.2006.076158
Open this paper in CoChat — free account

Abstract

Background: Most neuroendocrine tumors express chromogranin A (CgA). The posttranslational processing of neuroendocrine proteins such as CgA is often specific for the individual tumor. To cope with this variability and improve tumor diagnosis, we developed a processing-independent analysis (PIA) method to measure the total CgA product. Methods: For PIA, samples underwent trypsin treatment followed by measurement of CgA by the “CgA(340→)” assay, in which the antiserum binds an epitope starting at amino acid 340 of CgA and including amino acid residues located in the C-terminal direction. The diagnostic accuracy of the CgA PIA and 3 sequence-specific assays for CgA were evaluated on plasma samples from patients with neuroendocrine tumors and small-cell lung carcinomas. Furthermore, we investigated whether the CgA plasma concentrations correlated with the tumor burden. Results: Size-exclusion chromatography of plasma showed that CgA immunoreactivity mainly consisted of high–molecular-weight forms, indicating that neuroendocrine tumors may secrete large amounts of poorly processed CgA. Accordingly, trypsination of plasma from 54 patients with neuroendocrine tumors or small-cell lung carcinomas increased the CgA(340→) immunoreactivity up to 500-fold. Both the CgA(340→) assay and the PIA measured significantly higher plasma concentrations in patients with very extensive disease than in patients with less widespread disease. The diagnostic sensitivity was 0.91 when using the CgA(340→) assay and 0.82 using the CgA PIA. Conclusion: The CgA(340→) assay and CgA PIA are both useful for diagnosis of neuroendocrine tumors and small-cell lung carcinomas and both assays correlate with tumor burden.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1373/clinchem.2006.076158

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Diagnostic sensitivity and specificity of CgA depend on the assay type, analytic specificity and sensitivity of the antiserum employed.

    “Furthermore, diagnostic sensitivity and specificity depend on the assay type, analytic specificity and sensitivity of the antiserum employed [14], as does the fact that the CgA protein is heavily processed to smaller fragments [14,18,19,20].”

    From Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors (2020) · cites this paper as [14]

    The Discussion states that diagnostic sensitivity varies with assay specificity, and the evaluation of diagnostic accuracy reports different sensitivities for the four CgA assays (page numbers unavailable). Materials and Methods describes the epitopes recognized by the antisera. The copy does not establish that diagnostic specificity depends on assay type or on the antiserum’s analytic sensitivity. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

  • CgA PIA has demonstrated high diagnostic accuracy compared to the CgA340-348 RIA and other CgA assays without trypsin cleavage prior to measurement.

    “CgA PIA has demonstrated a high diagnostic accuracy (i.e., diagnostic sensitivity and specificity) compared to the CgA340-348 RIA and other CgA assays without trypsin cleavage prior to measurement [14,18].”

    From Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors (2020) · cites this paper as [14]

    Table 4A (Discussion; page unavailable) reports high diagnostic sensitivity for CgA PIA (0.82), exceeding two sequence-specific assays but below the CgA(340–348) RIA (0.91). The Discussion says both PIA and that RIA are sensitive tools and that determining which is superior requires a larger study. The cited passages do not establish comparative diagnostic specificity, so they support only part of the claimed diagnostic accuracy. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • Plasma chromogranin A (CgA) concentrations are related to tumor burden in patients with neuroendocrine tumors (NETs).

    “Plasma chromogranin A (CgA) is related to tumor burden and recommended in the follow-up of patients diagnosed with neuroendocrine tumors (NETs).”

    From Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors (2020) · cites this paper as [14]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Metadata

Authors
Børglum, T., Rehfeld, J. F., Drivsholm, L. B., & Hilsted, L.
Affiliations
  • University Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark
  • Rigshospitalet (DK)
  • Næstved Sygehus (DK)
Corresponding author
Hilsted, Linda
Venue
Clinical Chemistry
Publisher
Oxford University Press (OUP)
Published
2007-03-01
Volume
53
Issue
3
Pages
438-446
ISSN
  • 0009-9147 (ISSN-L)
  • 1530-8561
DOI
10.1373/clinchem.2006.076158
OpenAlex
W2132895322
Cited by
42
References
41
Citations by year
2024: 1 · 2023: 2 · 2021: 6 · 2020: 4 · 2019: 2 · 2017: 3 · 2016: 1 · 2015: 3 · 2014: 3 · 2013: 3 · 2012: 1
FWCI
2.06
Type
journal article
Language
en
Open access
closed
Licence
academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations
  • Clinical Chemistry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Sundhed og Sygdom, Det Frie Forskningsråd
  • Rigshospitalet
  • Medical Research Council
Topics
  • Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
  • Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
chromogranin A, neuroendocrine tumors, small cell lung cancer, trypsinization, plasma biomarkers, tumor burden, diagnostic sensitivity
MeSH terms
Adrenal Gland Neoplasms, Adult, Aged, Diagnosis, Differential, Female, Gastrointestinal Neoplasms, Humans, Immunoassay, Lung Neoplasms, Male, Middle Aged, Pheochromocytoma, Plasma, Reference Values, Severity of Illness Index, Carcinoma, Small Cell, Neuroendocrine Tumors, Chromogranin A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review